Navigation Links
ClearTrial Launches Version 2.7 of its Clinical Trial Operations Planning Software Featuring Advanced Portfolio Planning Capability
Date:3/3/2009

In ClearTrial v2.7, the newest version of the award-winning clinical trial software, ClearTrial introduces Portfolio Planning capability which enables clinical development organizations to roll up protocol-level study plans into portfolio-level forecasts in minutes. The software provides instant visibility to monthly budgets, monthly resource demand, and timelines across a program, business unit, therapeutic indication, region, service provider or any other dimension - a capability unique to the industry.

Chicago (PRWEB) March 3, 2009 -- ClearTrial (www.cleartrial.com), a leading provider of clinical trial software for clinical trial operations planning, budgeting, and outsourcing, announced today that it has released version 2.7 of its market-leading ClearTrial clinical trial software, which helps biopharmaceutical companies and clinical research organizations (CROs) accelerate and improve the planning and execution of their clinical trials. Today, 6 of the top 10 biotech companies and many of the largest companies in the industry rely on ClearTrial software to bring quality treatments to market faster, with less cost and effort.

With ClearTrial Portfolio Planning, available in the Enterprise Edition of ClearTrial v2.7, clinical development organizations can now roll up protocol-level study plans into portfolio-level forecasts in minutes, providing instant visibility to monthly budgets, monthly resource demand, and timelines across a program, business unit, therapeutic indication, region, service provider or any other dimension - a capability unique to the industry. And when protocol-level assumptions change, the software automatically updates the portfolio forecast in seconds.

With ClearTrial Portfolio Planning, clinical trial professionals can:


    Source: PRWeb
    Copyright©2009 Vocus, Inc.
    All rights reserved

    Page: 1 2 3 4

    Related biology technology :

    1. ClearTrial Selected to Lead Industry Panel on Managing Clinical Trial Cash Flow and Accruals at CBI Conference
    2. Video: Accera Launches Axona(TM), First Medical Food Therapy to Help Manage Mild-to-Moderate Alzheimers Disease
    3. Genencor Launches Accellerase(R) 1500, Next Step Toward Scale-Up of Cellulosic Ethanol
    4. EyeScience Launches Comprehensive Online Resource Devoted to Age-Related Macular Degeneration Education and Prevention
    5. Smith & Nephew Launches VISIONAIRE(TM) Patient Matched Technology for Total Knee Replacement
    6. CUREXO Technology Corporation Launches Its ROBODOC(R) Surgical System at Upcoming Orthopaedic Conference in Las Vegas
    7. BioSpace.com Launches a New Season of Industry Career Fairs
    8. Millipore Launches an Interactive Biological Pathway Tool Using GeneGos Manually Curated Pathway Maps
    9. Beginners Luck, or Creative Artists of the First Rank? Epeius Biotechnologies Launches Rexin-G eBook Tutorial
    10. Cephalons New Product Launches Pace Record 2008 Sales
    11. BioComp Pharma Launches First Generic Drug for Tindamax(R)
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:3/3/2015)... , March 3, 2015 /CNW/- SQI Diagnostics Inc. (TSX:V: ... proprietary technologies and products for advanced microarray diagnostics, ... CA, CFE  to its Management team. In his ... in its transition from a development stage to ... to advance the Company,s capital market strategy and ...
    (Date:3/3/2015)... , March 3, 2015  Regenicin, Inc. (OTC ... specializing in the development of and commercialization of regenerative ... and organs, announced today that it has received the ... Amarantus Bioscience Holdings, Inc. (OTC Bulletin Board: ... Agreement, Amarantus made the final payments due to Regenicin ...
    (Date:3/3/2015)... March 3, 2015  RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ... scientific journal, Expert Opinion on Biological Therapy , ... Zhenggang Zhang , at the Henry Ford Hospital ... Thymosin beta 4 (TB4) has the capacity to promote ... or more post-injury, leading to neurological recovery in each ...
    (Date:3/3/2015)... FRANCISCO , March 3, 2015 Kindred Biosciences, ... on saving and improving the lives of pets, announced today ... financial results on March 12, 2015 after the market close. ... Eastern Time that day. Interested parties may ... US, or (484) 756-4262 internationally, and using conference ID 98449349.  ...
    Breaking Biology Technology:SQI Diagnostics Appoints Chief Financial Officer 2SQI Diagnostics Appoints Chief Financial Officer 3Regenicin (RGIN) Receives $2.3 Million in Final Payment from Amarantus 2Regenicin (RGIN) Receives $2.3 Million in Final Payment from Amarantus 3Researchers at Henry Ford Hospital Propose Thymosin Beta 4 as Novel Way to Treat Neural Injury and Neurodegenerative Diseases 2Researchers at Henry Ford Hospital Propose Thymosin Beta 4 as Novel Way to Treat Neural Injury and Neurodegenerative Diseases 3
    ... ... that Maastricht based forensics lab DNalysis have successfully rolled out PatentSafe, protecting their forensic ... electronic repository. , ... Bracknell, UK (PRWEB) Feburary 10, 2010 -- Amphora Research Systems is pleased to announce ...
    ... , , , , , , , , , ... 12 /PRNewswire-Asia-FirstCall/ -- NeoStem, Inc.,(NYSE Amex: NBS ) ("NeoStem" ... and China , announced,today that it priced a public offering ... share. Net proceeds from the offering, after underwriting,discounts and commissions and ...
    ... , , ... 11 /PRNewswire-Asia/ -- 3SBio Inc. ( SSRX),("3SBio" or "the Company"), ... marketing,biopharmaceutical products, today announced its unaudited financial results,for the fourth quarter and ... Full Year 2009 Financial Highlights:, -- Total net ...
    Cached Biology Technology:Independent Forensics Company DNalysis Implement Amphora's PatentSafe Solution to Preserve and Secure Findings 2Independent Forensics Company DNalysis Implement Amphora's PatentSafe Solution to Preserve and Secure Findings 3NeoStem Prices Public Offering of 5,000,000 Shares of Common Stock 2NeoStem Prices Public Offering of 5,000,000 Shares of Common Stock 3NeoStem Prices Public Offering of 5,000,000 Shares of Common Stock 43SBio Inc. Announces Unaudited Fourth Quarter and Full Year 2009 Results 23SBio Inc. Announces Unaudited Fourth Quarter and Full Year 2009 Results 33SBio Inc. Announces Unaudited Fourth Quarter and Full Year 2009 Results 43SBio Inc. Announces Unaudited Fourth Quarter and Full Year 2009 Results 53SBio Inc. Announces Unaudited Fourth Quarter and Full Year 2009 Results 63SBio Inc. Announces Unaudited Fourth Quarter and Full Year 2009 Results 73SBio Inc. Announces Unaudited Fourth Quarter and Full Year 2009 Results 83SBio Inc. Announces Unaudited Fourth Quarter and Full Year 2009 Results 93SBio Inc. Announces Unaudited Fourth Quarter and Full Year 2009 Results 103SBio Inc. Announces Unaudited Fourth Quarter and Full Year 2009 Results 113SBio Inc. Announces Unaudited Fourth Quarter and Full Year 2009 Results 123SBio Inc. Announces Unaudited Fourth Quarter and Full Year 2009 Results 133SBio Inc. Announces Unaudited Fourth Quarter and Full Year 2009 Results 143SBio Inc. Announces Unaudited Fourth Quarter and Full Year 2009 Results 153SBio Inc. Announces Unaudited Fourth Quarter and Full Year 2009 Results 163SBio Inc. Announces Unaudited Fourth Quarter and Full Year 2009 Results 173SBio Inc. Announces Unaudited Fourth Quarter and Full Year 2009 Results 183SBio Inc. Announces Unaudited Fourth Quarter and Full Year 2009 Results 193SBio Inc. Announces Unaudited Fourth Quarter and Full Year 2009 Results 203SBio Inc. Announces Unaudited Fourth Quarter and Full Year 2009 Results 213SBio Inc. Announces Unaudited Fourth Quarter and Full Year 2009 Results 223SBio Inc. Announces Unaudited Fourth Quarter and Full Year 2009 Results 233SBio Inc. Announces Unaudited Fourth Quarter and Full Year 2009 Results 243SBio Inc. Announces Unaudited Fourth Quarter and Full Year 2009 Results 253SBio Inc. Announces Unaudited Fourth Quarter and Full Year 2009 Results 26
    (Date:2/5/2015)... 2015   Epic Sciences , a precision diagnostics company ... Murali Prahalad , Ph.D., president and CEO, is scheduled ... (PMWC) 2015: Silicon Valley, which is taking place at the ... on January 26-28, 2015. Dr. Prahalad ... Biomarkers." Last year, Epic Sciences was a finalist in the ...
    (Date:2/5/2015)... , Jan. 27, 2015   ... of globally deployed, innovative test solutions for ... the delivery of its TS-323 GENASYS ... Systems Company (LMSSC). GENASYS is a high-performance ... of mission-critical applications that require performance functional ...
    (Date:2/5/2015)... 28, 2015 NXT-ID, Inc. (NASDAQ: ... biometric authentication company focused on the growing mobile commerce ... Global Online CEO Conference on January 29 th ... Pereira , CEO of NXT-ID will present and host ... Wocket smart wallet and its full suite of biometric ...
    Breaking Biology News(10 mins):Epic Sciences to Present at Personalized Medicine World Conference 2015 on the Use of Circulating Tumor Cells as Cancer Biomarkers 2Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 2Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 3Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 4CEO of NXT-ID, Inc. to Discuss Company's Biometric Technologies at RedChip Online Conference January 29th 2CEO of NXT-ID, Inc. to Discuss Company's Biometric Technologies at RedChip Online Conference January 29th 3
    ... protecting us from diseases, but how does it do ... before dendritic cells move to the lymph nodes they ... much faster. Immature dendritic cells patrol the tissues in ... undergo a rigorous maturation process. During this maturation the ...
    ... St. Jude Children,s Research Hospital have discovered that a ... its identity that it requires the constant expression of ... The researchers showed that Prox1 acts as a two-way ... type of cell, called a lymphatic endothelial cell (LEC). ...
    ... of propensities acquired in the womb) reveals that consuming ... may significantly affect breast cancer outcomes for a mother,s ... Boston University is the first to link choline consumption ... first to identify possible choline-related genetic changes that affect ...
    Cached Biology News:Immune cells reveal fancy footwork 2Reprogrammable cell type depends on a single gene to keep its identity 2Eating eggs when pregnant affects breast cancer in offspring 2
    Rat Antibody to Mouse TCR VB8.1,8.2:FITC Recognises the V beta 8.1 and V beta 8.2 determinants of the murine T cell receptor. Specificity: mouse TCR VB8.1 and 8.2...
    fli-1...
    Vesicle Associated Membrane Protein (VAMP 1/2)...
    Anti-Mouse Valpha 2 TCR, Purified (Clone B20.1) (rat IgG2a)...
    Biology Products: